Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2023, titled "(1)Zydus receives final approval from the USFDA for Apixaban Tablets, 2.5 mg and 5 mg and(2) Zydus receives final approval from the USFDA for Olmesartan Medoxomil andHydrochlorothiazide Tablets".
Press Release Feb 28 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release detailing two final approvals from the USFDA for its medications. The first approval is for Apixaban Tablets, which are used to reduce the risk of stroke and blood clots. The second approval is for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, used for treating high blood pressure. Both drugs will be manufactured at Zydus's facilities in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 24 2023
- Press Release Feb 20 2023
- Press Release Feb 17 2023
- Press Release Feb 15 2023
- Press Release Jan 27 2023
Later from Zydus Lifesciences
- Press Release Mar 02 2023
- Press Release Mar 03 2023
- Press Release Mar 07 2023
- Press Release Mar 09 2023
- Zydus Lifesciences Limited Press Release Mar 15 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences